Lynparza is indicated for the treatment in patients with advanced ovarian cancer Lynparza is indicated for the treatment in patients with HER2 – negative metastatic breast cancer.
Myriad genetic Laboratories
Olaparib is generic form of brand name Lynparza
Olaparib belongs to type of oral poly (adenosine diphosphate–ribose) polymerase inhibitor which has promising antitumor action in patients with metastatic breast cancer and a germline BRCA mutation.
Lynparza is a prescription drug which used under the supervision of medical practioners
Olaparib belongs to targeted therapy. Olaparib is a type of poly (ADP-ribose) polymerase (PARP) enzyme inhibitor, contain PARP1, PARP2, and PARP3. PARP enzymes are included in DNA transcription, cell cycle managing, and DNA repair. Olaparib is aneffective oral PARP inhibitor which induces synthetic lethality in BRCA 1/2 deficient tumor cells via the formation of double-stranded DNA breaks which cannot be precisely repaired, which cause disruption of cellular homeostasis and cell death.
DOSAGE AND ADMINISTRATION
Maintenance treatment of recurrent ovarian cancer
The tablet recommended dose is 300mg (two 150mg – mg tablets) PO BID
Continue treatment until disease progression or unacceptable toxicity
Monotherapy for advanced BRCA – mutated ovarian cancer :
Thetablet recommended dose is 300mg (two 150mg – mg tablets) PO BID
The capsules recommended dose is 400mg (eight 50mg- mg capsules) PO BID
Continue treatment until disease progression or unacceptable toxicity.
Maintenance treatment for advanced BRCA-mutated ovarian cancer :
The tablet recommended dose is 300mg (two 150mg – mg tablets) PO BID Follow the treatment until disease progression, undesirable toxicity o
r completion of 2 years of treatment
Finishing of 2 years of treatment:
• Patients with full response (no radiologic evidence): discontinue treatment
• Patients with indication of disease and may asset from continuous treatment: cure beyond 2 years.
Common side effects :
• Decreased white blood cell count
• Abdominal pain
• Upper respiratory tract infection
• Decreased neutrophils
• Musculoskeletal pain
• Decreased platelet count
• Decreased Haemoglobin
• Fatigue (including weakness)
• Increased serum creatinine
Less common side effects of patients administrating Olaparib :
• Skin rash
• Back pain
• Taste changes
• Urinary tract infection
• Decreased appetite
• Shortness of breath.
Haematological toxicity will cause in patients treated with Lynparza contain diagnoses or findings of generally mild or moderate anaemia, neutropenia, thrombocytopenia and lymphopenia.
When Lynparza monotherapy administrated to patient the incidence of myelodysplastic syndrome will occur.
On basis of mechanism of action (PARP inhibition), Lynparza could cause risk to fetal when administered to a pregnant woman.
Lynparza combination with strong or moderate CYP3A inhibitors is not recommended.